BioSpace News Archive

Tessa Therapeutics Ltd., a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced clinical data from an ongoing Phase 1 study of TT11X, an allogeneic “off the shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy being co-developed by Baylor College of Medicine and Tessa.

Servier announced Phase 3 data demonstrating that TIBSOVO® in combination with the chemotherapy azacitidine significantly improved event-free survival and overall survival compared to azacitidine plus placebo in adults with previously untreated IDH1-mutated acute myeloid leukemia who are not candidates for intensive chemotherapy.

Four studies being presented during the 63rd American Society of Hematology Annual Meeting and Exposition point to the transformative role immunotherapies are playing in the treatment of major blood cancers.

Kite, a Gilead Company, announced results from the primary analysis of ZUMA-7, a global Phase 3 study evaluating Yescarta® as a one-time infusion, in a head-to-head study against standard of care for adults with large B-cell lymphoma who relapsed or were refractory to first-line treatment.

Kite, a Gilead Company, announced five-year follow-up data from the pivotal ZUMA-1 trial of Yescarta® in adult patients with refractory large B-cell lymphoma.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from two studies evaluating the efficacy and safety of IMBRUVICA® plus venetoclax as a potential fixed-duration treatment in adult patients with previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new analyses illustrating responses that first-line treatment with DARZALEX® -based regimens may be able to achieve, including a potential survival benefit for DARZALEX® in combination with lenalidomide and dexamethasone.

Three studies being presented during the 63rd American Society of Hematology Annual Meeting and Exposition throw a spotlight on novel approaches to screening for and treating blood diseases, as well as an unexpected, potential association between a blood abnormality and Alzheimer’s disease.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab.

Imago BioSciences, Inc., a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms, presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis.